Literature DB >> 33787027

Juvenile nasal angiofibroma significant locoregional involvement

Juan Ramon Y Cajal Calvo1, Pablo Vela Gajón2, Carlota Bello Franco3, Maria Jose Gimeno Peribañez4, Gloria Tejero Garcés Galve5.   

Abstract

Juvenile nasal angiofibroma is a benign tumor characterized by abundant vascularization and a tendency to hemorrhage. Despite its benign histology, it can present locally expensive growth that usually presents bone remodeling and the mass effect of adjacent stuctures. We present the case of a 15-year-old patient who came to the emergency department of our center for recurrent epistaxis. After physical examination, it was decided to carry out imaging tests (CT an MRI) that reveal the presence of a large hypervascular mass in the right nostril and maxillary sinus. The patient undergoes surgery after embolization of the tumor. Universidad Nacional de Córdoba

Entities:  

Keywords:  nasopharynx; epistaxis; angiofibroma

Mesh:

Year:  2021        PMID: 33787027      PMCID: PMC8713376          DOI: 10.31053/1853.0605.v78.n1.28538

Source DB:  PubMed          Journal:  Rev Fac Cien Med Univ Nac Cordoba        ISSN: 0014-6722


  3 in total

1.  Treatment outcomes of juvenile nasopharyngeal angiofibroma according to surgical approach.

Authors:  Dong-Woo Hyun; Ji-Hwan Ryu; Yoo-Suk Kim; Kyu-Bo Kim; Won Shik Kim; Chang-Hoon Kim; Joo-Heon Yoon
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2010-10-28       Impact factor: 1.675

2.  Progressive epistaxis in two young males: Classic presentations of juvenile nasopharyngeal angiofibroma in unusual locations.

Authors:  Christopher Harker Hunt; Jonathan M Morris; Peter U Lee; Harry Cloft
Journal:  Neuroradiology       Date:  2010-02-02       Impact factor: 2.804

3.  Preoperative angiography and external carotid artery embolization of juvenile nasopharyngeal angiofibromas in a tertiary referral paediatric centre.

Authors:  D Ballah; D Rabinowitz; A Vossough; S Rickert; B Dunham; K Kazahaya; A M Cahill
Journal:  Clin Radiol       Date:  2013-08-02       Impact factor: 2.350

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.